论文部分内容阅读
目的观察罗格列酮对代谢综合征(metabolic,syndrome,MS)患者腹部脂肪分布的影响及其与糖脂代谢的关系。方法 2004-2007年在我科住院诊断为MS的住院患者88例分为治疗组(n=44)和对照组(n=44),治疗组给药罗格列酮(马来酸罗格列酮4mg,1次/d),对照组不给予任何胰岛素增敏剂。2组患者常规控制血糖、血脂、血压,持续时间为12周。最后检测血糖、血脂、C反应蛋白(C-reactive protein,CRP)、尿微量白蛋白(microalbuminuria,MAU),并采用超声测量腹壁脂肪、腹内脂肪厚度。结果与治疗前比较,2组治疗后血糖、血压均显著降低(P<0.05),但治疗组甘油三酯(TG)显著降低而高密度脂蛋白胆固醇(HDL-c)显著增高(P<0.05,P<0.01),同时CRP、腹内脂肪、MAU水平显著降低[CRP:(4.53±4.13)mg/Lvs(2.94±3.11)mg/L;腹内脂肪厚度:(53.41±17.00)mmvs(45.14±16.94)mm;MAU:(67.79±88.55)mg/24hvs(20.22±26.59)mg/24h,P<0.05,P<0.01)。结论罗格列酮可减少MS腹内脂肪含量,抑制炎症反应,改善脂代谢紊乱,可能与减轻肾损害有关。
Objective To observe the effect of rosiglitazone on abdominal fat distribution in patients with metabolic syndrome (MS) and its relationship with glucose and lipid metabolism. Methods A total of 88 hospitalized patients diagnosed as MS in our department from 2004 to 2007 were divided into treatment group (n = 44) and control group (n = 44). Rosiglitazone maleate Ketone 4mg, 1 time / d), the control group did not give any insulin sensitiser. Two groups of patients routine control of blood glucose, blood lipids, blood pressure, duration of 12 weeks. The blood glucose, blood lipids, C-reactive protein (CRP) and microalbuminuria (MAU) were detected. The thickness of abdominal fat and abdominal fat were measured by ultrasound. Results Compared with those before treatment, blood glucose and blood pressure were significantly decreased in both groups (P <0.05), but triglyceride (TG) and HDL-c in treatment group were significantly increased (P <0.05 (P <0.01, P <0.01). CRP, intra-abdominal fat and MAU levels were significantly lower than those in control group [CRP: 4.53 ± 4.13 mg / L vs 2.94 ± 3.11 mg / ± 16.94) mm; MAU: (67.79 ± 88.55) mg / 24h vs (20.22 ± 26.59) mg / 24h, P <0.05, P <0.01). Conclusions Rosiglitazone can reduce the intra-abdominal fat content of MS, inhibit the inflammatory reaction and improve the disturbance of lipid metabolism, which may be related to the reduction of renal damage.